Your browser doesn't support javascript.
loading
Single-dose quinidine treatment inhibits mexiletine oxidation in extensive metabolizers of debrisoquine.
Broly, F; Vandamme, N; Caron, J; Libersa, C; Lhermitte, M.
Afiliação
  • Broly F; Laboratoire de Pharmacologie Hospitalière, Faculté de Médecine de Lille, France.
Life Sci ; 48(26): PL123-8, 1991.
Article em En | MEDLINE | ID: mdl-2046473
ABSTRACT
Urinary elimination of unchanged mexiletine, p-hydroxymexiletine (PHM), hydroxymethylmexiletine (HMM) and mexiletine N-glucuronide conjugate (MGC) was investigated before and after treatment with quinidine. All subjects were phenotyped as extensive metabolizers for debrisoquine oxidation. The total recovery of mexiletine and metabolites was significantly reduced after quinidine pretreatment. It is concluded that pretreatment with a very low dose of quinidine inhibits markedly the elimination of both major mexiletine metabolites (PHM and HMM) and likely decreases the overall elimination of mexiletine. That should lead to changes in mexiletine disposition and have clinical consequences during combination therapy with both drugs.
Assuntos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quinidina / Debrisoquina / Mexiletina Limite: Humans Idioma: En Ano de publicação: 1991 Tipo de documento: Article
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quinidina / Debrisoquina / Mexiletina Limite: Humans Idioma: En Ano de publicação: 1991 Tipo de documento: Article